A Study of the Interaction between Hepatitis C Virus Infection and Pulmonary Disorders: Assessment of Interferon Gamma and Alpha-1-Antitrypsin
| Autor: | Amal Saad-Hussein, Dalia El-Lebedy, Dina Kandil, Mona Kafoury, Nada Ezzeldin, Hebatallah Fraouk, Mohamed Radwan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
lung disease
Hepatitis C virus medicine.medical_treatment alpha-1-antitrypsin lcsh:Medicine genotype medicine.disease_cause IFN gamma Pulmonary function testing DLCO Interferon medicine Interferon gamma Lung business.industry lcsh:R General Medicine Hepatitis C Immunotherapy medicine.disease digestive system diseases medicine.anatomical_structure Immunology HCV business medicine.drug |
| Zdroj: | Open Access Macedonian Journal of Medical Sciences, Vol 2, Iss 1, Pp 40-45 (2014) Open Access Macedonian Journal of Medical Sciences; Vol 2, No 1 (2014): Mar 15 (OAMJMS); 40-45 |
| ISSN: | 1857-9655 |
| Popis: | Objectives: To study lung diseases in chronic HCV infection and vice versa and to find immunological and/or hereditary interrelating factors.Material and Methods: Study included 134 individuals, all were subjected to screening for anti-HCV antibodies by ELISA, HCV-RNA by real time PCR, pulmonary function tests, quantitative assay of interferon gamma and alpha-1- antitrypsin in serum by ELISA and genotyping of alpha-1- antitrypsin gene by Light Cycler PCR.Results: 76.5% of chronic HCV patients had abnormal PFT (P = 0.03), mainly reduced DLCO and reversible airway obstruction, and 41.6% of chest diseased patients were HCV-positive with a significant decrease in large and small airways functions. Interferon therapy improved PFT parameters. Only 33% of chronic HCV infection affected by chest abnormality responded to interferon therapy while 50% of chest free patients did. Serum IFN-γ was higher in HCV and chest patients than in control (P=0.02). All serum α1AT deficient patients had M/null genotype.Conclusions: A pathogenic role of chronic HCV infection in lung diseases is evident. Interferon treatment may reduce chest complications and improve pulmonary functions. However, chest affection may reduce the response to interferon treatment. M/null genotype of α1AT gene might play a role in chronic HCV infection and chest co-affection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|